Navigation Links
Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S.
Date:9/2/2009

    BERLIN, September 2 /PRNewswire/ --

    - Asset Purchase Agreement Signed for Marketed Prescription Products
      Desonate(R) and NeoBenz(R) Micro

Intendis GmbH, which is part of Bayer HealthCare, announced today that it has signed an agreement to acquire two prescription dermatology product lines from SkinMedica, Inc., a dermatology company based in Carlsbad, CA, USA.

Both Desonate(R) and NeoBenz(R) Micro are currently marketed in the U.S. by SkinMedica, Inc. Under the transaction, which is still subject to the necessary regulatory approvals, Intendis will acquire all commercial rights, including assigned contracts and intellectual property related to the two product lines. The deal is expected to close in the Fall of 2009.

"We are currently seeing solid growth of our existing portfolio of prescription dermatologicals in the U.S. With the addition of these two high-quality product lines we expect to build on this dynamic and to substantially strengthen our presence in this key strategic business," stated Marc Lafeuille, President and CEO of the Intendis Group. In 2008, the company grew by 18.7% on a currency-adjusted basis in the U.S.

Desonate(R) is a low potency topical corticosteroid for the treatment of mild to moderate atopic dermatitis, an inflammatory skin disease. Formulated in a waterbased Hydrogel vehicle, it is indicated for patients as young as 3 months. NeoBenz(R) Micro is a benzoyl peroxide medication for the treatment of mild to moderate acne vulgaris. Its special formulation allows for a gradual release of the active ingredient which allows for an effective treatment with only low irritation.

"We are pleased that this agreement with Intendis will allow us to devote investments to continued growth of our remaining dermatology business," said Mary Fisher, President and CEO of SkinMedica. "We look forward to expanding our pipeline of innovative products for the improvement of skin appearance and the treatment of dermatologic conditions."

About Intendis

Intendis is an integrated pharmaceutical company based in Berlin, Germany. As part of Bayer HealthCare, Intendis is completely dedicated to Dermatology and focuses on the development, manufacturing and marketing of high quality, innovative topical therapies, targeted to treat skin disorders. The current product portfolio comprises treatments of eczema disorders including atopic dermatitis, as well as psoriasis, acne, rosacea, hemorrhoids and fungal skin infections (mycoses). Find out more at http://www.intendis.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. SkinMedica markets and sells, primarily to dermatologists, both prescription pharmaceutical products and physician-dispensed, non-prescription skin care products. SkinMedica is based in Carlsbad, California. For more information, visit: http://www.skinmedica.com.

Desonate(R), EpiQuin(R) Micro, NeoBenz(R) Micro, SkinMedica(R), TNS Recovery Complex(R) and VANIQA(R) are registered trademarks of SkinMedica, Inc and affiliates.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

    Contact Intendis:
    Tobias Rockel, Phone: +49-30-520075-650
    E-mail: tobias.rockel@intendis.com

    Contact SkinMedica:
    Mary Fisher, Phone: +1-760-448-3680
    E-mail: mfisher@skinmedica.com



'/>"/>
SOURCE Bayer HealthCare AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bayer CropScience Announces Investment of $25 Million for Institute Site
2. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
3. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
4. Neptune Products to be commercialized by BAYER HealthCare
5. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
6. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
7. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
8. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
9. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
10. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
11. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... solutions for clinical development reported today that it is launching two new additions ... company will be demonstrating new capabilities at the DIA 2017 Annual Meeting in ...
(Date:6/16/2017)... ... , ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced ... Chelsea Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and ... to secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... 2017 , ... DuPont Industrial Biosciences (DuPont) announced that Jan ... Bloomberg’s 2017 Sustainable Business Summit: Seattle this Thursday, June 15, at 4:10 ... panel titled “Developing a Corporate Renewables Strategy.” , “Consumers want to buy ...
(Date:6/14/2017)... ... ... Diagenode, a leading global provider for complete solutions for ... technology specific for ChIP-sequencing from the CeMM for low ... (ChIP-seq) allows the study of histone modifications and transcription ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):